Below is a selection of recent market reports that are specifically relevant to licensing and business development issues. They can be used to benchmark deal values as well as understanding recent trends in biotech and pharma licensing.
Partnering and M&A Deals in Pharma and Biotech Yearbook 2010
Current Partnering, Jan 2011
The Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2010. The report allows you to view all the partnering, alliances and M&A deals announced worldwide. In-depth review of every big pharma company provides the reader with a breakdown of that company’s dealmaking during 2010 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2010, complete with a hyperlink to the deal record online. The report also provides a comprehensive directory of partnering and M&A activity during 2010.
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals
GlobalData, Jan 2011
GlobalData's report, covering Q4 2010, is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
The Royalty Rate Report 2010
PharmaVentures, Mar 2010
A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, this report is a “must read” for anyone involved in deal making who wants to get the maximum value from their next deal. It offers clear guidance on the best methodologies to use when calculating Royalty Rates to assist with vital decision making, opinions and advice from leading industry deal makers on how to calculate Royalty Rates and reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: “What do royalties mean in terms of value?” and “Where do royalties fit within the deal?”.
Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Current Partnering, Jun 2010
The Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report detailed understanding and analysis of how and why companies enter pre-clinical stage licensing/business development and other forms of partnering arrangement. The focus of the report is on partnerships for pre-clinical stage compounds where partners have joined forces to exploit these early stage opportunities. This is an early stage of partnering undertaken by commercial entities with the objective of utilizing promising drug candidates. The report provides access to average pre-clinical stage deal payment terms as announced between the parties.
Pharmaceutical M&A Overview 2009
Datamonitor, Dec 2009
After a slump in M&A activity following the global economic downturn and with the looming threat of the 2011 "patent cliff", Pharma companies are looking to expand geographically and enhance their pipelines in order to offset future losses. Two high growth areas which have been an intrinsic focus of recent M&A activity are biologic therapies and the rapidly-growing emerging markets. This report provides an overview of recent trends within the M&A landscape in terms of type of acquisition and targeted healthcare sectors as well as evaluation of recent mega mergers: Pfizer-Wyeth, Roche-Genentech, Merck-Schering, and Abbott-Solvay.
Trends in Pharmaceutical Deal Making
PharmaVentures, Jun 2009
This report is a must-have report for all involved in business development, marketing or competitive intelligence in understanding what lies behind such deals and how they come about. In deal making, it can be hard to pick the optimum deal type for your situation. Even the most accomplished deal maker is unlikely to have been involved in each and every type of deal. This indispensable report answers numerous key questions including: What is the rationale for different deal structures? What is the most relevant deal type to use in a particular situation? What are the key issues that must be considered for each deal type? How do I value these deals?
